GYRE THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 6, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | Before market open | $29.10M | $-0.12 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $22.50M | $-0.10 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | $37.20M | $-0.02 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | After market close | $30.60M | $0.03 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | During market hours | $26.80M | $0.00 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | After market close | $22.10M | $0.00 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | During market hours | $27.90M | $0.00 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $25.50M | $0.01 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 7, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | Full year 2026 | $100.50M to $111.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Gyre Therapeutics filed with the SEC
1 September 2026 A Global Innovator Expanding And Reinventing Protein Degrader
Regulation FD disclosure · EX-99.1 to Form 8-K
1 August 2026 Building A New Protein Degrader Company For Unmet Medical Needs
Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gyre Therapeutics Appoints Three New Members to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Results of operations · EX-99.1 to Form 8-K/A
Item 9.01. Financial Statements and Exhibits.
Results of operations · EX-99.2 to Form 8-K/A
A Fully-Integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory
Regulation FD disclosure · EX-99.1 to Form 8-K
A Fully-integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory
Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
A Fully-Integrated Biopharmaceutical Company Featuring a Robust Pipeline of
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre‑NDA Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Developing Anti-Fibrotic Therapeutics for Chronic Organ Diseases H.C.
Other events · EX-99.1 to Form 8-K
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
May 22,2025 Hydronidone (F351) Phase 3 Trial in CHB-Associated Liver Fibrosis -
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation April 2025 Developing Anti-Fibrotic Therapeutics for
Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
The following information was originally prepared and published by GNI Group Ltd. in Japanese as it contains timely disclosure materials to be
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Notification of Conclusion of License Agreement by Gyre Pharmaceuticals Co.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The following information was originally prepared and published by GNI Group Ltd. in Japanese as it contains timely disclosure
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
(Security Code: 2160, TSE Growth)
Regulation FD disclosure · EX-99.1 to Form 8-K
(3Q of 23rd Fiscal Period)
Regulation FD disclosure · EX-99.1 to Form 8-K
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
(Security Code: 2160, TSE Growth)
Regulation FD disclosure · EX-99.1 to Form 8-K
CATALYST BIOSCIENCES ANNOUNCES COMPLETION OF BUSINESS COMBINATION WITH BEIJING CONTINENT PHARMACEUTICALS AND IMPLEMENTATION
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K